[{"Assets_0_Q1_USD":278379000.0,"CommonStockSharesOutstanding_0_Q1_shares":19040000.0,"EarningsPerShareBasic_1_Q1_USD":-0.26,"EarningsPerShareDiluted_1_Q1_USD":-0.26,"NetIncomeLoss_1_Q1_USD":-4980000.0,"StockholdersEquity_0_Q1_USD":268168000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":19038000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":19038000.0,"Ticker":"ENTA","CIK":"1177648","name":"ENANTA PHARMACEUTICALS INC","OfficialName":"Enanta Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20161231","fy":"2017.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1492537180.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20170209"}]